

)
)
FEDERAL TRADE COMMISSION,)
)
Plaintiff,)
)
v.) **Cv. 98-3114 (TFH)**
)
MYLAN LABORATORIES, INC.,)
CAMBREX CORP.,)
PROFARMACO S.R.L., and)
GYMA LABORATORIES)
OF AMERICA, INC.,)
)
Defendants.)
)
 _____)
)
THE STATE OF CONNECTICUT, *et al.*,)
)
Plaintiffs,)
)
v.) **Cv. 98-3115 (TFH)**
)
MYLAN LABORATORIES, INC.,)
CAMBREX CORP.,)
PROFARMACO S.R.L.,)
GYMA LABORATORIES OF)
AMERICA, INC.,)
and SST CORP.,)
Defendants.)
)

Upon consideration of the parties' proposed amended scheduling orders and the supporting memoranda, it is hereby

ORDERED that the Second Amended Scheduling Order in the above-captioned cases is amended as follows:

(1) Each side may take no more than 40 third-party depositions, and each party's third-party witness list may not exceed 35 witnesses;

(2) Defendants may take no more than 40 depositions of state employees on the subject of damages;

(3) By February 15, 2000, defendants shall provide a list of no more than seven products in addition to clorazepate and lorazepam on which they wish to take discovery related to causation, and by February 22, 2000, plaintiffs shall provide a list of no more than five products in addition to clorazepate and lorazepam on which they wish to take discovery related to causation;

(4) Any party must receive at least five days notice for a deposition, and the party being deposed must agree to produce the witness within 14 days of the date originally noticed or seek an order from this Court; and

(5) Upon good cause shown, either party may move to take additional depositions in excess of the limits set forth above. Prior to filing such a motion, the parties are directed to consider the use of representative depositions upon stipulation that other witnesses would testify similarly on direct and cross-examination. See William M. Schwarzer, Managing Antitrust and Other Complex Litigation, 68-69 (1982). Any party seeking to take additional depositions shall accompany its motion with an explanation for why representative depositions are inadequate.

(6) These cases shall proceed on the schedule attached to this Order.

Thomas F. Hogan
United States District Judge

February ____, 2000

<u>DATE</u>	<u>ACTIVITY</u>
February 15, 2000	Defendants provide a list of the seven products on which they intend to take discovery for causation.
February 22, 2000	Plaintiffs provide list of their five counter-example products for discovery.
February 29, 2000	Mylan, Gyma and SST provide updated discovery to plaintiffs.
March 7, 2000	Plaintiffs provide preliminary third-party witness list which may not exceed 35 witnesses.
March 14, 2000	Cambrex and Profarmaco provide updated discovery to plaintiffs.
March 17, 2000	Defendants provide preliminary third-party witness list which may not exceed 35 witnesses.
July 14, 2000	Fact discovery closes.
July 28, 2000	Plaintiffs provide expert reports (rebuttal experts excluded).
August 28, 2000	Defendants provide expert reports.
September 28, 2000	Plaintiffs produce rebuttal expert reports.
October 23, 2000	Expert discovery closes.
November 22, 2000	Closing date for filing summary judgment motions.
December 22, 2000	Oppositions to summary judgment motions due.
January 22, 2001	Replies to oppositions to summary judgment motions due.
March 14, 2001	Final pretrial conference held. Trial to begin within 30 to 60 days of the final pretrial conference pursuant to Local Rule 206(c)(13).